January 27, 2022
Mirror Biologics Appoints Joel Kanter as Chairman of the Board of Directors
Adi Raviv Continues as Chief Executive Officer and President

December 26, 2021
Mirror Biologics Announces Appointment of Dr. David Feinberg as Chief Medical Officer

December 9, 2021
Mirror Biologics, Inc. Announces Close of a $14 Million Financing Round

November 17, 2021
Mirror Biologics Announces Issuance of US Patent Covering Next Generation Therapeutic Vaccine Technology for Treatment of Cancer and Infectious Disease

September 10, 2021
Mirror Biologics, Inc. Announces Initial Clearance for Phase II/III Clinical Trial (ALIVE) in Advanced Liver Cancer

August 2, 2021
Announcing Appointment of Global CRO Parexel to provide Regulatory & Access Consulting Services

July 14, 2021
Mirror Biologics, Inc. Announces Initiation of AlloStim® Phase I/II Universal Viral Vaccine Clinical Trial (ALLOPRIME) in Healthy Adults Over 65 Years Old

July 8, 2021
Mirror Biologics, Inc. Announces Initiation of AlloStim® Phase IIB Clinical Trial (STIMVAX) in Patients with Metastatic Colorectal Cancer

May 12, 2021
Mirror Biologics, Inc. Announces Appointment of Interim CEO